Cytek Biosciences, Inc. (CTKB) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Maintaining the midpoint of full year 2026 total revenue guidance and narrowing the range to $208 million to $211 million “We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business,” said Wenbin Jiang, CEO of Cytek Biosciences." exhibit |
| Q3 FY2026 | "The increase in expenses for the three months ended September 30, 2026 was primarily driven by higher personnel costs, offset by lower engineering expenses." exhibit |
| Q3 FY2026 | "General and administrative expenses were $18.4 million for the third quarter of 2026, a 14% increase compared to the third quarter of 2025, primarily due to higher litigation-related expenses, partially offset by lower compensation and severance expenses and the non-recurrence of a write-off of deferred offering costs in the prior-year period." exhibit |
| Q3 FY2026 | "Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, compared to $262.0 million as of June 30, 2026, a decrease of $5.7 million. 2026 Outlook Cytek Biosciences is maintaining the midpoint of its revenue outlook for the full year 2026 and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates." exhibit |
| Q3 FY2026 | "expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; Cytek’s intention to pursue additional post-trial remedies, including a potential appeal; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue." exhibit |
| Q2 FY2026 | "Updates full year 2026 total revenue guidance to $207 million to $212 million, raising the midpoint by $1 million “Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences." exhibit |
| Q2 FY2026 | "Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026, a decrease of $0.2 million. 2026 Outlook Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CTKB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CTKB
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CTKB/"><img src="https://veritasdata.dev/embed/CTKB.svg" alt="CTKB earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CTKB/)
Script
<script async src="https://veritasdata.dev/embed/CTKB.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CTKB"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.